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With primary central nervous system lymphoma (PCNSL) being a rare disease, the subtype of Burkitt lymphoma (BL) presenting as
a sole CNS lesion is an even more exceptional diagnosis. A case of coexistent primary CNS Burkitt lymphoma (PCNSBL) with
cerebral palsy (CP) is presented. A 55-year-old Caucasian male presented with increasing bilateral lower extremity weakness
above his baseline in addition to signs of increased intracranial pressure. Four abnormal enhancing masses were detected on
MRI with biopsy results consistent with Burkitt lymphoma. Complete staging workup was completed with no evidence of extra-
CNS disease noted on PET/CT, bone marrow biopsy, or cerebral spinal fluid analysis. The patient was treated with intravenous
as well as intrathecal chemotherapy and found to be in a complete remission at six months. Recurrence in the CNS was
observed four months later with treatment consisting of whole brain radiation as well as intrathecal chemotherapy. Thirty
months after diagnosis, the patient remains disease-free. To our knowledge, this is the first case of PCNSBL in the setting of CP.
A review of literature regarding treatment options in this controversial setting is provided.
1. Introduction
Primary central nervous system lymphoma (PCNSL) has
historically been an uncommon disease entity since it was
first discovered. Recent reviews, however, indicate that cases
continue to arise at increasing numbers [1–3]. Incidence rose
three-fold between the years of 1973 and 1984; however, the
rate of increase is currently trending toward stabilization [4].
This is perhaps due to the invention of highly active antire-
troviral therapy (HAART) for acquired immunodeficiency
syndrome (AIDS) as immunocompromised individuals
remain at 300% increased risk for PCNSL [3], and the
average age of diagnosis is 40 in the immunosuppressed
population versus 55–61 years of age in those who are immu-
nocompetent [3]. Even as the incidence of PCNSL rises, it
remains a rare disease with a mere 7% incidence rate. The
subset of those individuals with primary CNS Burkitt lym-
phoma (PCNSBL) constitutes an even scarcer population
comprising just 3–5% of the PCNSL cases [1–3]. Only 36
cases of PCNSBL were found worldwide after a thorough
literature review (Table 1).
With such diminutive evidence on the most effective way
to treat these patients, no standard of care exists, and the
chosen therapy has been anything but uniform. Many have
elected various combinations of intravenous (IV) chemo-
therapy, intrathecal (IT) chemotherapy, and radiation ther-
apy. A backbone of IV high-dose methotrexate (HD-MTX)
proves to be the most significant prognostic variable with
regard to treatment [3]. However, the optimal role for IT
MTX as well as radiation has yet to be defined.
Recently, there has been doubt amongst professionals
whether whole brain radiation therapy (WBRT) should be
implored for these patients. In those who receive WBRT,
approximately 61% relapse within the radiation field, and
the risk of significant neurotoxicity, is 25–35% at 5 years with
death occurring in one-third of those patients [4–6]. This
toxicity proves especially detrimental in individuals greater
than 60 years of age [4], with recent assertions that using
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Table 1: Reported PCNSBL cases. Cy: cyclophosphamide; OS: overall survival; WBRT: whole brain radiation therapy; CHOP:
cyclophosphamide, doxorubicin, vincristine, and prednisone; Dex: dexamethasone; IVIG: intravenous immunoglobulin; MTX: methotrexate.
Author Year Age/sex How it is diagnosed (LP versus mass) Treatment and OS
Gawish [18] 1976 8/M
Left frontoparietal mass extending across
midline and through the skull
Complete resection with recurrence. Subtotal
resection with Cy. OS of 3 years
Valsamis et al. [19] 1976 6m/M
Left parietal, bilateral temporal, and post
pituitary mass with abdominal and
periaortic nodal involvement
Resection, steroids, WBRT, and spinal irradiation
with recurrence, IT MTX. OS of 23 months
Tanaka et al. [20] 1977 49/M Right thalamus to midbrain mass Subtotal resection. OS of 4.5 years
Tanaka et al. [20] 1977 58/M Right temporal mass Subtotal resection. Recurrence. OS 3 months
Tanaka et al. [20] 1977 42/M Left deep parietal to occipital mass
Pred with partial resection. Recurrence.
Vincristine and Cy with radiation. Vincristine,
bleomycin, Cy, steroids. OS of 2.5 years
Giromini et al. [11] 1981 11/M Left temporooccipital mass Complete resection
Hegedüs [21] 1984 50/F Right lower parietal lobe mass Post mortem finding
Kobayashi [22] 1984 55/F Right temporoparietal mass
Complete resection. Recurrence with reresection.
OS of 2 months
Pui et al. [23] 1985 6/M T2-5 mass
Laminectomy and CHOP (without prednisone).
OS> 2 years
Pui et al. [23] 1985 7/M C7-T4 mass
Laminectomy, radiation, dex, and Cy.
Recurrence. OS of 5 months
Pui et al. [23] 1985 12/M T7-10 mass
Laminectomy, CHOP (substituting dex for
prednisone). OS of 4 months
Mizugami et al. [24] 1987 6/M T10 mass
Near complete resection, radiation, and
chemotherapy. Leukemic transformation then CSF
recurrence. IT MTX and cranial irradiation.
OS of 20 months
Mizugami et al. [24] 1987 5/M Epidural T12-L4 mass
Near complete resection, radiation, and
chemotherapy with recurrence. OS of 7 months
Mizugami et al. [24] 1987 7/F T11 mass
Near complete resection. Spinal radiation and
chemotherapy with progression of disease.
OS of 3 months
Shigemori et al. [25] 1991 49/F Left frontal lobe mass
Resection, radiation, CHOP, and IT MTX.
OS of >6 months
Tekkök et al. [12] 1991 5/M
Parasellar mass, extending to bilateral
sphenoids and sella turcica
Partial resection, craniospinal radiation, CHOP, and
IT MTX/cytarabine/prednisone. OS> 18 months
Toren et al. [26] 1994 6/F CSF
Steroids, IVIG, doxorubicin, vincristine, HD MTX,
with IT MTX, cytarabine, and hydrocortisone.
Changed to CHOP with MTX and IT MTX,
cytarabine, hydrocortisone. OS of >2 years
Mora and Wollner [7] 1999 18/M T11 mass
Laminectomy with CHOP substitute daunorubicin
for doxorubicin and radiation. Relapse and refused
further treatment. OS> 8 months
Mora and Wollner [7] 1999 9/M Epidural T9-11 mass
Laminectomy, dex, radiation, and CHOP
(substituting daunorubicin for doxorubicin).
Recurrence and given chemotherapy via LSA3
protocol. Second recurrence, received
palliative radiation. OS> 1 year
Spath-Schwalbe et al. [27] 1999 40/M Cerebellum and pons masses MTX and WBRT. OS> 1 year
Wilkening et al. [28] 2001 43/F
L2-3 epidural tumor involving the
dura and cauda equina
Complete resection, radiation, IT MTX, and
MTX with ifosfamide and CHOP (with dex
substituted for prednisone). OS of >2 years
Monabati et al. [29] 2002 49/F Right parietal mass
Complete resection, CHOP, and craniospinal
radiation. Refused further treatment.
OS of >6 months
Daley et al. [30] 2003 13/F L1-2 epidural mass
Complete excision, CHOP with MTX, and IT
MTX and cytarabine and steroids. OS of >5 years
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WBRT in children is no longer necessary or acceptable due to
significant risk of long-term neurotoxicity [7]. The German
PCNSL Study Group is the largest and only phase III ran-
domized trial comparing IV chemotherapy±WBRT which
revealed no significant difference in overall survival (OS)
(44.2 versus 59.0 months, p = 0 78) when WBRT was added
to HD-MTX-based chemotherapy in those patients with a
complete response (CR) [8]. In a subset of patients who did
not reach a CR, however, the addition of WBRT did show
prolonged progression-free survival (PFS) (5.0 versus 2.9
months, p = 0 002) but did reveal a difference in OS (27.4
versus 18.2 months, p = 0 119) [8].
Several different therapeutic options, including IT che-
motherapy and complete surgical resection, have also been
questioned. As IV HD-MTX crosses the blood-brain bar-
rier, many believe IT only increases toxicity with little to
no additional benefit. Complete resection of the tumor
has also been challenged in the past as it potentially
increases neurologic deficits without any survival benefit
[5]. Recently, the German PCNSL Study Group-1
(GPSG-1) trial has refuted this, stating there may be signifi-
cant PFS [2]. Discrepancies may be attributed to the advances
that have been made in neurosurgical techniques over the last
decade [2].
Patients with PCNSL have an extremely poor prognosis,
with an OS of approximately 12–18months [1, 3, 9]. Without
treatment, this number dwindles to 1.5–3.3 months [10].
Therefore, it is imperative that this disease be treated with
the best available option to improve the expected survival
of these individuals. Here, we present a case of an adult
HIV-negative male with PCNSBL in the setting of cerebral
palsy (CP) and our approach to treatment with long-term
follow-up.
2. Case
A 55-year-old Caucasian male with past medical history of
cerebral palsy (CP) presented with nausea, vomiting, thirty-
pound weight loss, and worsening bilateral lower extremity
weakness for one month. A computerized tomography
(CT) angiogram of the brain revealed a suprasellar mass
facilitating transfer to our institution for further manage-
ment. Magnetic resonance imaging (MRI) of the brain indi-
cated abnormal enhancement along the ependymal margin
of the frontal horns of the bilateral lateral ventricles with four
distinct abnormal enhancing mass lesions in the hypothala-
mus (11× 12× 13mm), pineal gland (8× 8× 9mm), the tri-
gon of the right lateral ventricle (5× 5× 4mm), and the
Table 1: Continued.
Author Year Age/sex How it is diagnosed (LP versus mass) Treatment and OS
Shehu [31] 2003 8/M Left temporal and right orbit masses
Cy, vincristine, and MTX with IT cytosine
arabinoside. OS of 11 months
Abel et al. [32] 2006 50/M Central and right thalamus mass Unknown
Gobbato et al. [15] 2006 38/M
Right frontotemporoparietal
subdural mass
Craniotomy. OS of 11 days
Kozáková et al. [33] 2008 60/F Sellar/pituitary mass Complete resection
Gu et al. [34] 2010 75/F Third and left lateral ventricle masses WBRT. OS of >9 months
Takasu et al. [35] 2010 71/M Hypothalamus and third ventricle mass Partial resection and WBRT
Jiang et al. [36] 2011 14/M Right lateral ventricle mass
Complete resection, radiation, and MTX,
vincristine, predisone, and leucovorin.
OS of >18months
Lim et al. [10] 2011 43/F
Medulla oblongata mass,
CSF involvement
MTX, vincristine, and procarbazine with
IT MTX and WBRT. OS of 7 months
Akhaddar et al. [37] 2012 13/F
Right infratemporal and cavernous/
maxillary/sphenoethmoidal sinus mass
Chemotherapy
Jiang et al. [38] 2012 69/M
Right temporal and occipital lobe,
cervical spine, and cauda equina masses;
CSF involvement
DLBCL/BL subtype. WBRT, spinal
radiation with recurrence. HD MTX and
cytarabine with rituximab
Yoon et al. [39] 2012 10/M
Suprasellar, cerebellum, and 3rd
ventricle masses; CSF involvement
HD MTX and cytarabine with IT cytarabine,
MTX, and hydrocortisone. OS of >7 years
Yoon et al. [39] 2012 32m/M
Sellar mass extending to
orbit/sphenoid, CSF involvement
HD MTX and cytarabine with IT cytarabine,
MTX, and hydrocortisone. Relapse, treated with
IT cytarabine, MTX, and hydrocortisone with
WBRT and spinal radiation. Then received
prednisone, vincristine, and cyclophosphamide
with IT. OS of 9 months
Alabdulsalam et al. [40] 2014 18/M 4th ventricle mass
Craniotomy with HD MTX with
rituximab-CHOP and IT MTX, cytarabine, and
hydrocortisone. OS of >18months
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foramen of Magendie (7× 6× 9mm) which demonstrated
restriction diffusion indicating hypercellularity (Figure 1).
An endoscopic biopsy of the third ventricle floor lesion
was performed with pathology revealing sheets of intermedi-
ate size monotonous lymphoid cells displaying high nuclear-
to-cytoplasmic ratio with dispersed chromatin and indistinct
nucleoli. Numerous apoptotic cells and mitotic figures with
foci of necrosis were observed. The tumor cells displayed
CD 20 with coexpression of CD 10 and were negative for
BCL 2, BCL 6, CD 3, and CD 5. EBER in situ hybridization
was also negative. Fluorescent in situ hybridization was pos-
itive for [11, 12] (MYC/IHG) fusion in 97% of the cells and
loss of BCL2 in 96%. These results appeared to be consistent
with Burkitt lymphoma.
Staging workup was obtained which only revealed con-
cern for extra cranial disease present at T12-L1 and L2-L3
consistent with subarachnoid nodular pial metastases on
MRI of the lumbosacral spine. PET/CT disclosed no evidence
of extra-CNS disease. A lumbar puncture and bone marrow
biopsy were performed and found to be negative for disease.
In the absence of extra-CNS disease, the patient was diag-
nosed with PCNSBL.
Patient was started on IV HD-MTX (3.5 grams per
meter squared) and cytarabine (2 grams per meter
squared) per Ferreri regimen [13] with the addition of
IT MTX/cytarabine every 21 days for four cycles. Dose
was reduced by 25% for cycle three due to persistent cytope-
nias and toxicity including renal dysfunction with delayed
MTX clearance. A repeat brain MRI was obtained after 6
months which indicated complete remission with no
evidence of disease (Figure 2).
Four months later, the patient began having generalized
weakness with visual disturbances and headaches. A repeat
brain MRI at that time revealed interval development of
markedly abnormal signal in the pons extending to the mid-
brain and dorsal medulla. Repeat cerebral spinal fluid (CSF)
analysis showed rare atypical lymphocytes consistent with
relapse of lymphoma. He underwent WBRT, receiving 30
Gray (Gy) over 17 fractions with an additional boost to the
midbrain lesion with 9Gy in 8 fractions. Currently, he is
disease-free at 30 months s/p diagnosis.
3. Discussion
To our knowledge, our patient is the only PCNSBL case with
a past medical history of CP. No literature was discovered
that revealed a connection between these two diseases, and
further research may be warranted if similar cases develop
in the future. It would have been easy to dismiss the present-
ing symptoms as part of his CP; therefore, caution must be
taken to not be blinded by a patient’s past medical history
in attempting to decipher the etiology of new symptoms. Pri-
mary CNS lymphoma should remain a consideration for
those presenting with neurological symptoms regardless of
their history.
The optimal treatment for PCNSBL continues to elude
us, and no standard of care exists at this time. The paucity
of cases provides little opportunity for randomized con-
trolled trials; therefore, clinicians have been forced to extrap-
olate based upon recommendations for Burkitt lymphoma
residing outside as well as PCNSL regimens. Many of the
reported cases of PCNSBL used HD-MTX +/−, some varia-
tion of cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) therapy. A few studies attempted addi-
tional agents such as ifosfamide and procarbazine, but had
little success. Several used IT MTX alone or in combination
with cytarabine and steroids.
Our treatment decision was based upon the Ferreri regi-
men, which is the only randomized trial for PCNSL [13].
Since our patient suffered from the added rarity of Burkitt
lymphoma subtype, the addition of IT chemotherapy was
made based on standard practice for extra-CNS Burkitt lym-
phoma as it has a high incidence of CNS penetration. While
there has been some debate regarding the need for IT chemo-
therapy in addition to IV HD-MTX, these patients were
mostly non-Burkitt type (diffuse large B cell) PCNSL. Even
with the baseline cognitive deficits of our patient, he was able
to tolerate an aggressive chemotherapy regimen that
included IT and eventually WBRT without any permanent
neurological complications to date. Although he did develop
some mild delirium while hospitalized for WBRT and IT
MTX after relapse, this promptly resolved prior to discharge.
The decision at that time was made to withhold any further
Figure 1: MRI brain, T1 sagittal + gadolinium, demonstrated lesions
within hypothalamus, pineal gland, trigon of the right lateral
ventricle, and foramen of Magendie at diagnosis.
Figure 2: MRI brain, T1 sagittal + gadolinium, revealing complete
resolution of all four mass lesions after receiving IV and IT
chemotherapy.
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IT therapy as no further evidence of disease was present and
the risk of toxicities outweighed the current benefits. He
remains disease-free at 30 months.
The role of IT therapy has been challenged in the face of
HD-MTX therapy being able to cross the BBB. Ferreri et al.
have shown that there is no survival benefit when using IT
in addition to HD-MTX with regard to PCNSL of all types,
with 2-year OS rates of 51± 5% with IT versus 50± 6% with-
out IT [14]. There are also reports of increased neurotoxicity
when adding concurrent IT to HD-MTX with no survival
benefit [8]. Neither of these studies separated those with Bur-
kitt subtype, however. Therefore, our decision for IT admin-
istration was based upon extrapolation from accepted
therapy for extra-CNS Burkitt lymphoma being IT MTX/
Ara-C in addition to systemic chemotherapy.
We present a case of relapsed lymphoma that responded
to WBRT of 30 Gray in 17 fractions with boost of 9 Gray in 8
fractions which was tolerated well with a complete response
(CR), and no evidence of disease at 18 months after radiation
was completed. Many studies have attempted to investigate
the benefits and toxicities associated with the use of WBRT,
which challenges the prior approach to this entity. There
seems to be a trend away from WBRT, especially in those
individuals> 60 years of age and children with no evidence
of residual disease after IV chemotherapy, as long-term neu-
rocognitive consequences have been found to outweigh the
benefit gained by these patients with neurotoxicity being fatal
even without evidence of recurrent disease [4].
Recent studies have shown no OS benefit when adding
upfront WBRT to HD-MTX-containing regimens. Ferreri
et al. have shown an OS of 25± 4% at 2 years with WBRT
alone which was significantly inferior to both MTX-
containing chemotherapy as well as MTX combined with
WBRT, revealing a 2-year OS of 34± 10% and 45± 3%,
respectively [14]. This OS difference between WBRT with
MTX versus MTX alone was not significant; therefore, it is
suggested that those individuals at a high risk of neurotoxic-
ity forego WBRT unless relapse or refractory disease is
apparent. We therefore chose to forego WBRT in the initial
setting, reserving it for relapsed disease in our patient. Debate
also exists regarding the optimal dose of WBRT, as each
study utilized different fractions and dosages. Hyperfractio-
nation has also been noted to have increase toxicity as com-
pared to standard dosage with neurotoxicity rates of 23%
and 3.7%, respectively [5]. This has been shown to be most
prevalent in those receiving> 50 Gray [9].
The concept of complete surgical resection has fallen
under scrutiny in recent years as well. Previously, many sub-
scribed to complete resection of the mass with recent reports
challenging this citing an increase in postoperative neurolog-
ical deficits with no OS benefit [2, 3, 15]. Currently, the
decision for excision when CNS lesions are the only areas
of disease is made on a case by case basis with regard to
tumor location and expected postsurgical deficits.
Despite adequate initial treatment with chemotherapy
with or without WBRT, approximately 40–50% of PCNSL
patients relapse within the first 5 years [3]. This obviates
the need for obtaining better treatment modalities, not only
first line but also for relapsed or refractory disease. The
median post relapse survival rate approximates 2 months
with a 2-year OS of 8% [3]. Our patient is now 18 months
status post a second CR. A few small studies have evaluated
the role of bone marrow transplant as a potential treat-
ment for PCNSL in the relapsed and refractory setting as
these individuals have a significantly increased risk of death
[2, 16, 17]. Randomized phase II trials must be undertaken
to thoroughly evaluate this option with regard to such a
specific disease population.
Our patient subscribed to the current statistics of recur-
rence of disease within the first five years despite a complete
response to initial treatment. He is currently disease-free for
18 months after reinduction with WBRT, which is longer
than the average survival of such individuals, and remains
without any significant neurotoxicity. Using our approach
of IV and IT chemotherapy in PCNSBL upfront and reserv-
ing WBRT for the relapsed setting, our patient has far
exceeded the median post relapse survival rate. This suggests
a potential benefit to our approach. Regardless of the rela-
tively favorable outcome of our patient, it remains that clear
optimal treatment continues to be elusive. Substantial
advances are required with regard to PCNSBL, as it remains
a significant challenge to patients and physicians alike.
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